Attention-deficit hyperactivity disorder (ADHD) has emerged in the last few years as the most commonly diagnosed and treated psychiatric disorder in the paediatric population. In 1980's, methylphenidate (MFD) a psychomotor stimulant drug, was approved in Spain for the symptomatic therapy of ADHD. Since then, MFD has become one of the most extensively prescribed and studied treatment for ADHD both in children and adults. In this paper, the main pharmacological issues of MFD are reviewed, focusing on its pharmacokinetics in conventional (blood and urine) and non-conventional (hair, oral fluid and sweat) biological matrices, its pharmaceutical preparations, therapeutic levels and side effects.
- Attention deficit and hyperactivity disorder
- Therapeutic drug monitoring
Papaseit, E., García-Algar, O., Simó, S., Pichini, S., & Farré, M. (2013). Metilfenidato en el tratamiento del trastorno de déficit de atención con hiperactividad en pediatría: Monitorización en matrices biológicas. Anales de Pediatria, 78(2), 123.e1-123.e10. https://doi.org/10.1016/j.anpedi.2012.08.015